Nattokinase-heparin exhibits beneficial efficacy and safety-an optimal strategy for CKD patients on hemodialysis

Glycoconjugate Journal
Hao WuFengjiao Zhang

Abstract

Heparin is a widely used anticoagulant in hemodialysis (HD) for patients with chronic kidney disease (CKD); however, it entails the risk of thrombus formation due to heparin-induced thrombocytopenia. Indeed, CKD patients on HD are associated with excessive mortality from cardiovascular disease due to their prothrombotic profile. Therefore, it would be a significant breakthrough to develop a thrombolytic adjuvant that facilitates heparin to achieve its proper anticoagulant efficiency at a much lower dose for greater safety. Nattokinase (NK), a valuable dietary supplement possessing strong fibrinolytic and thrombolytic activity, was reported to interact with heparin and thereby the beneficial efficacy of NK-heparin was investigated herein. NK-heparin induced a synergistic enhancement of clotting time both in vitro and in vivo evaluations, whereas the overall fibrinolytic activity was only marginally enhanced. Moreover, it was demonstrated for the first time that NK induced potent degradation of all three chains of fibrinogen. In particular, NK-heparin markedly reinforced the fibrinolysis activity of NK, which may underlie, at least in part, the mechanism by which NK-heparin benefited their overall thrombolytic and anticoagulant a...Continue Reading

References

Oct 1, 1995·Biological & Pharmaceutical Bulletin·M FujitaS Nishimuro
Nov 1, 1996·The American Journal of Medicine·T E Warkentin, J G Kelton
Jul 29, 1999·Annals of Emergency Medicine·T M OsbornW R Gaasch
Sep 1, 1999·The International Journal of Biochemistry & Cell Biology·S HerrickG Laurent
Dec 7, 2002·Toxicon : Official Journal of the International Society on Toxinology·Robin Doley, Ashis Kumar Mukherjee
Jul 10, 2003·Lancet Neurology·Michael Daffertshofer, Michael Hennerici
Jun 7, 2006·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Ming-Wai Tai, Burgunda V Sweet
Sep 28, 2007·Cardiovascular & Hematological Disorders Drug Targets·R CastelliF Fabris
Dec 25, 2007·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Anetta UndasWiesława Tracz
Apr 11, 2009·Nutrition Research·Chien-Hsun HsiaNae-Cherng Yang
Jun 6, 2009·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Krystyna PawlakDariusz Pawlak
Jan 7, 2010·Journal of Thrombosis and Haemostasis : JTH·K WanakaY Nakajima
Feb 18, 2011·Journal of Thrombosis and Thrombolysis·Adam Cuker
Apr 12, 2011·Thrombosis and Haemostasis·Katharina Hess, Peter J Grant
Aug 5, 2014·Carbohydrate Research·Benito CasuGiangiacomo Torri
Jun 26, 2015·Scientific Reports·Yuko KurosawaTakafumi Hamaoka
Sep 29, 2015·Glycoconjugate Journal·Fuming ZhangRobert J Linhardt
Apr 9, 2016·Seminars in Thrombosis and Hemostasis·Rustem I Litvinov, John W Weisel
Jun 25, 2016·Clinical Journal of the American Society of Nephrology : CJASN·Richard L AmdurUNKNOWN CRIC Study Investigators
Jan 18, 2018·Journal of Pharmaceutical Sciences·Yin ChenRobert J Linhardt
Mar 3, 2018·International Journal of Molecular Sciences·Juan R Muñoz-CastañedaMaría E Rodríguez-Ortiz

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
surface plasmon resonance

Software Mentioned

NK
SPSS

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

© 2022 Meta ULC. All rights reserved